The Efficacy of Bamlanivimab in Reducing Emergency Department Visits and Hospitalizations in a Real-world Setting

Open Forum Infect Dis. 2021 Jun 10;8(7):ofab305. doi: 10.1093/ofid/ofab305. eCollection 2021 Jul.

Abstract

Bamlanivimab, a monoclonal antibody targeting the spike protein of severe acute respiratory syndrome coronavirus 2, is available for ambulatory treatment of coronavirus disease 2019 (COVID-19). This real-world study confirms the efficacy of bamlanivimab in reducing hospital admissions and emergency department visits among high-risk outpatients with mild to moderate COVID-19 illness and reveals a trend toward improved mortality.

Keywords: COVID-19; bamlanivimab; outcomes; treatment.